Betta Pharmaceuticals prepares and tests new KRAS inhibitors for cancer
July 5, 2023
Research at Betta Pharmaceuticals Co. Ltd. has led to the identification of new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
